Syncrosome is a preclinical CRO dedicated to In vivo pharmacology since 12 years now and with a strong competency in Efficacy and Pharmacokinetics.
One of our departments is dedicated to Cardiovascular with relevant models in Ischemia and heart failure, Pulmonary Arterial Hypertension, coagulation…
Lyna Messous, Scientist in Syncrosome, will present our last results during the GRRC congress, in Bordeaux, France on April 12-13, 2012.
Our poster: “In vivo rat acute myocardial Ischemia-Rep...
Are you attending "Preclinical Safety and Efficacy Testing for New Drugs" Annual meeting in Zurich?
I would like to invite you to meet Syncrosome representatives:
Sandra Robelet, CNS Study Director,
Emmanuelle Bettendorf, Account Manager,
at "Preclinical Safety and Efficacy Testing for New Drugs", Nov. 29 - Dec. 1 in Zurich.
Syncrosome is a Preclinical Drug Evaluation Company specialised in human health - we perform pharmacological in vivo studies on physiopathological models.
Syncrosome is a Preclinical Drug Evaluation Company specialised in human and animal health in vivo pharmacological studies. Syncrosome has the professional expertise to complete studies independently or to work in parallel with in-house research teams, after preliminary in vitro screenings - www.syncrosome.com